Profiling of tumor genetics is becoming an increasingly important part of the battle against cancer, and Next Generation Sequencing (NGS) is emerging as a particularly powerful way to quickly and affordably establish baseline tumor genetics.
Platforms such as MiSeq™ and Ion Torrent™ are now routinely used to interrogate tumors using pre-defined cancer panels such as Ampliseq™ or Truseq™.
The range of steps involved in NGS workflows, combined with the sheer number of biomarkers being screened, has the potential to create unprecedented levels of variability. In order to generate results with confidence, it is important to manage these potential sources of variability, from sample extraction and sample selection through to sequencing and variant calling.
Horizon's cell line-derived Reference Standards enable you to:
|Product Name||Catalog ID||Description||Price||Quantity|
|HD825||The EGFR Multiplex cfDNA Reference Standard Set is a cell line-derived, clinically relevant co...||
|HD780||The Multiplex I cfDNA Reference Standards are highly-characterized, biologically-relevant refe...||
|HD817||Developed using clinically-relevant mutations in an artificial matrix to give you full control...||
|HD816||Developed using clinically-relevant mutations in synthetic plasma to give you full control of ...||
|HD786||The Structural Multiplex cfDNA Reference Standard provides biologically relevant quality contr...||